Individualized Location-based rTMS for Migraine Treatment: A Multicenter Clinical Study

Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Jul 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment for people who suffer from migraines, which are severe headaches that happen at least four times a month. The treatment uses a technique called repetitive transcranial magnetic stimulation (rTMS), which involves using magnetic pulses to gently stimulate certain areas of the brain. The study is comparing two ways of targeting the brain during treatment: one is the traditional method, and the other is a new, personalized approach that focuses on the individual’s specific brain activity. Researchers want to see which method works better at reducing the number of migraine days and improving quality of life.

To join the study, participants need to be adults between 18 and 65 years old who have had migraines for at least a year, with symptoms starting before age 50. They must experience migraines on at least four days every month. People with certain health conditions, like metal implants or severe anxiety, or who are pregnant, won’t be eligible. If accepted, participants will be closely monitored before and after treatment for up to three months. They’ll keep migraine diaries and have various tests to check headache frequency, intensity, medication use, and how migraines affect their daily life. The study also looks at changes in brain activity and some biological markers to better understand how the treatment works. This research could help doctors tailor migraine treatments more effectively in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged between 18 and 65 years; both men and women.
• • Diagnosis of migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-III), with first onset before age 50 and a history of migraine for more than 1 year.
• • Migraine frequency of ≥4 days per month during both the 3 months prior to the screening period and the screening period itself.
• • Informed consent documents are signed, and subjects are cooperative with the evaluation and rTMS treatment, having been informed of known and potential risks and available alternative treatments.
• Exclusion Criteria:
• • Patients with contraindications to TMS (e.g., metal implants, pacemakers).
• • Severe anxiety or depression (HAMD score \>35, HAMA score \>29).
• • History of migraine prophylactic drug adjustment during the screening and treatment period.
• • Aphasia or cognitive dysfunction (MMSE score ≤23).
• • Pregnancy or lactation.
• • Clinicians assess severe comorbidities that are not treatable.